Latest News

Big multiple sclerosis breakthrough: Phase 1 trial safely resets patients' immune systems and reduces attack on myelin protein

A phase 1 clinical trial for the first treatment to reset the immune system of multiple sclerosis (MS) patients showed the therapy was safe and dramatically reduced patients' immune systems' reactivity to myelin by 50 to 75 percent. The therapy used billions of patients' own specially processed blood cells to create tolerance to myelin, the insulating layer that forms around nerves. In MS, the immune system attacks myelin. The approach left the normal immune system intact.
View full story

Post your comment.


  • Trust your aha! moments: Experiments show they're probably right

  • Scientists use synthetic gene and magnets to alter behavior of mice, fish

  • Teen girls see big drop in chemical exposure with switch in cosmetics

  • Female traders can reduce market crashes, expert says

  • Toxic byproduct of hemoglobin could provide clues for cerebral hemorrhage and Creutzfeldt-Jakob Disease

  • Clinician communication reduced distress related to the detection of incidental nodules

  • Talk about yourself on social media?

  • New mothers with postpartum psychiatric disorders face increased risk of suicide, study shows

  • Combining two techniques to 'rewire' the brain may improve arm, hand movement for stroke survivors

  • Scientists map roots of premeditated, violent 'intent' in animal brain